A Phase II Study of Single-Agent Gemcitabine as a Second-Line Treatment in Advanced Non-Small Cell Lung Cancer: P-1–145


    loading  Checking for direct PDF access through Ovid

Abstract

Abstract unavailable for this article.


    loading  Loading Related Articles